These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Addictiveness of central stimulants. Dackis CA; Gold MS Adv Alcohol Subst Abuse; 1990; 9(1-2):9-26. PubMed ID: 1974121 [TBL] [Abstract][Full Text] [Related]
5. Overcoming cocaine or stimulant addiction. Medications offer modest help; vaccines are in development. Harv Ment Health Lett; 2009 Mar; 25(9):6-7. PubMed ID: 19368038 [No Abstract] [Full Text] [Related]
6. Adverse effects of stimulant drugs in a community sample of drug users. Williamson S; Gossop M; Powis B; Griffiths P; Fountain J; Strang J Drug Alcohol Depend; 1997 Mar; 44(2-3):87-94. PubMed ID: 9088780 [TBL] [Abstract][Full Text] [Related]
7. Nondependent stimulant users of cocaine and prescription amphetamines show verbal learning and memory deficits. Reske M; Eidt CA; Delis DC; Paulus MP Biol Psychiatry; 2010 Oct; 68(8):762-9. PubMed ID: 20605137 [TBL] [Abstract][Full Text] [Related]
8. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Ciccarone D Prim Care; 2011 Mar; 38(1):41-58. PubMed ID: 21356420 [TBL] [Abstract][Full Text] [Related]
9. The treatment of stimulant dependence. Schuckit MA Addiction; 1994 Nov; 89(11):1559-63. PubMed ID: 7841871 [TBL] [Abstract][Full Text] [Related]
10. The prevention of stimulant misuse. Kaplan CD; Husch JA; Bieleman B Addiction; 1994 Nov; 89(11):1517-21. PubMed ID: 7841865 [TBL] [Abstract][Full Text] [Related]
11. Responding to global stimulant use: challenges and opportunities. Farrell M; Martin NK; Stockings E; Bórquez A; Cepeda JA; Degenhardt L; Ali R; Tran LT; Rehm J; Torrens M; Shoptaw S; McKetin R Lancet; 2019 Nov; 394(10209):1652-1667. PubMed ID: 31668409 [TBL] [Abstract][Full Text] [Related]
12. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Stoops WW; Rush CR Expert Rev Clin Pharmacol; 2014 May; 7(3):363-74. PubMed ID: 24716825 [TBL] [Abstract][Full Text] [Related]
15. Iboga interactions with psychomotor stimulants: panacea in the paradox? Szumlinski KK; Maisonneuve IM; Glick SD Toxicon; 2001 Jan; 39(1):75-86. PubMed ID: 10936624 [TBL] [Abstract][Full Text] [Related]
16. Medication development for addictive disorders: the state of the science. Vocci FJ; Acri J; Elkashef A Am J Psychiatry; 2005 Aug; 162(8):1432-40. PubMed ID: 16055764 [TBL] [Abstract][Full Text] [Related]
17. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Vocci FJ; Montoya ID Curr Opin Psychiatry; 2009 May; 22(3):263-8. PubMed ID: 19307968 [TBL] [Abstract][Full Text] [Related]
18. Biological effects of central nervous system stimulants. Holman RB Addiction; 1994 Nov; 89(11):1435-41. PubMed ID: 7841853 [TBL] [Abstract][Full Text] [Related]
19. Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Howell LL; Negus SS Adv Pharmacol; 2014; 69():129-76. PubMed ID: 24484977 [TBL] [Abstract][Full Text] [Related]
20. Norepinephrine and stimulant addiction. Sofuoglu M; Sewell RA Addict Biol; 2009 Apr; 14(2):119-29. PubMed ID: 18811678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]